RESET THERAPEUTICS
Reset Therapeutics is a biopharmaceutical company formed to discover, develop and commercialize new therapeutics that modulate the circadian system, the body’s network of internal molecular clocks.
RESET THERAPEUTICS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2008-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.resettherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
(650)235-4150
Email Addresses:
[email protected]
Total Funding:
53.62 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Maps GoDaddy DNS Google Google Cloud OpenResty Google Adsense Google Cloud Global Multi-Region
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Eidos Therapeutics
Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
Mast Therapeutics
Mast Therapeutics is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Current Advisors List
Founder
Official Site Inspections
http://www.resettherapeutics.com
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 15.197.148.33
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Reset Therapeutics"
Reset Therapeutics - Crunchbase Company Profile & Funding
Reset Therapeutics is a biopharmaceutical company formed to discover, develop and commercialize new therapeutics that modulate the circadian system, the body’s network of …See details»
www.resettherapeutics.com
Www.resettherapeutics.comSee details»
Reset Pharma
Reset Pharma is a neuro-biotechnology company dedicated to improving mental health through novel pathways. We exist to help people move beyond the psychological trauma of a life-threatening diagnosis. Our focus lies where …See details»
Reset Therapeutics - VentureRadar
Website: http://www.resettherapeutics.com. Develops therapeutics to treat metabolic disorders related to circadian rhythm dysfunction and narcolepsy. Bio tech-Careers. Associated sectors: …See details»
Reset Therapeutics - Contacts, Employees, Board Members
Reset Therapeutics has 2 board members and advisors, including Ross Bersot. Reset Therapeutics, a biopharmaceutical company, develops and commercializes products that …See details»
CDD Spotlight Interview with Paul Humphries, Reset …
Apr 17, 2014 · Dr. Humphries is the Vice President, Chemical Sciences at Reset Therapeutics. Previously, he was a Senior Principal Scientist at Pfizer working in the area of Metabolic Diseases.See details»
Reset Therapeutics - Tech Stack, Apps, Patents & Trademarks
Nov 17, 2024 · Reset Therapeutics, a biopharmaceutical company, develops and commercializes products that modulate the circadian system of the human body.See details»
Reset Therapeutics Announces Expansion of its Drug Discovery …
SAN FRANCISCO, Jan. 7, 2015 /PRNewswire/ -- Reset Therapeutics, a company dedicated to the discovery and development of novel drugs that restore the body's natural 24-hour …See details»
Jessica SUN | Director | Reset Therapeutics, California ...
Jessica SUN, Director | Cited by 938 | of Reset Therapeutics, California (RESETTHERAPEUTICS) | Read 31 publications | Contact Jessica SUNSee details»
Research programme: orexin receptor modulators - Reset …
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.See details»
Orexin Receptor Agonists for the Treatment of Excessive Daytime ...
Sep 1, 2014 · Reset Therapeutics proposes to develop orexin receptor agonists for the treatment of narcolepsy. Narcolepsy is a debilitating lifelong disorder characterized by excessive daytime …See details»
Newsroom – Reset Pharma
Reset Pharmaceuticals, Inc. (Reset Pharma) announced today that Stephen Ross, M.D., Chair of Reset Pharma’s… Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, …See details»
Reset Therapeutics - VentureRadar
Website: http://www.resettherapeutics.com. Develops therapeutics to treat metabolic disorders related to circadian rhythm dysfunction and narcolepsy. Bio tech-Careers. Associated sectors: …See details»
Reset Pharmaceuticals Enters into Exclusive Worldwide
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma) a privately-held biotechnology company focused on developing and commercializing …See details»
Recommended Stories - Yahoo Finance
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma) a privately-held biotechnology company focused on developing and commercializing …See details»
Alkermes to Co-Develop Reset’s Orexin Receptor Modulators
Mar 17, 2016 · Reset Therapeutics said today it will partner with an affiliate of Alkermes to discover, develop, and commercialize novel orexin receptor modulators using Reset’s drug …See details»
Daniel OPPENHEIMER | Chief Operating Officer | Reset …
Daniel OPPENHEIMER, Chief Operating Officer | Cited by 174 | of Reset Therapeutics, California (RESETTHERAPEUTICS) | Read 8 publications | Contact Daniel OPPENHEIMERSee details»
Reset Pharma partners with Filament to license psilocybin drug
Sep 1, 2023 · Reset Pharmaceuticals has entered a licensing agreement with Filament Health for psilocybin drug PEX010 for treating demoralisation syndrome. The agreement grants Reset …See details»
Sandoz and Pear Therapeutics announce launch of reSET® for
Nov 20, 2018 · reSET is a 12-week (90-day) prescription digital therapeutic to be used in conjunction with outpatient clinician-delivered care. reSET offers interactive treatment modules …See details»
Pear Therapeutics, Novartis announce commercial launch of reSET
Nov 20, 2018 · reSET is a 12-week digital cognitive behavioral therapy program accessed through an app and designed to accompany outpatient care delivered by a physician.See details»